louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02560064: Length of Small Bowel. How Can Standardise Measurement and Why?
Official title: Length of Small Bowel. How Can Standardise Measurement and Why?
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Small/Large Bowel
Lead sponsor: Inonu University
Sponsor class: OTHER
First posted: 2015-09-25
Enrollment: 45
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Power analyse was done. Study include at least 44 patients.

Brief summary: Measurement of the small bowel length studied by anatomists, surgeons and radiologists. Results were highly different among these series. Technical and mechanical factors have major effects on measures. Investigators decided to reach a standardization for the measurement of small bowel length.

Detailed description: Small bowel length will be measure in patients undergoing intraabdominal surgery. This will be establish by two surgeon from Treitz ligament to ileocecal valve two, consecutively. For measurement, a tape will place to antimesenteric, mesenteric border and the midline between these two sides.

Exclusion criteria include patients with inflammatory bowel disease, peritonitis, prior abdominal surgery.

Demographic data, patients clinical details and small bowel length will be recorded.

Eligibility criteria: Inclusion Criteria:

* Candidate for abdominal surgery

Exclusion Criteria:

* Inflammatory bowel disease
* History of intraabdominal surgery
* peritonitis

Primary outcomes:
measure: Length of Small Bowel. How Can Standardise Measurement and Why?
timeFrame: postop 1 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Inonu University, Faculty of Medicine
name: Cuneyt Kayaalp
role: STUDY_DIRECTOR
References:
Clinical trial NCT00979264: Centers for Education on Research and Therapeutics - Heart Failure: Targeted Intervention Study
Official title: Centers for Education on Research and Therapeutics - Heart Failure: Targeted Intervention Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Heart Failure
Keywords: Quality Improvement
Lead sponsor: Duke University
Sponsor class: OTHER
Collaborators: name: Agency for Healthcare Research and Quality (AHRQ)
First posted: 2009-09-17
Enrollment: 147
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The objective of this study is to evaluate whether a quarterly feedback, education and performance improvement site-based intervention has a greater impact on quality performance and adherence to evidenced-based guidelines than existing on-demand feedback. This study will use a randomized design to compare changes in quality performance and adherence to selected measures among hospitals using existing on-demand reports and general quality improvement (QI) efforts versus those receiving intensive, targeted QI feedback via reports, teleconferences, webinars, and specialized tool kits.


Eligibility criteria: Inclusion Criteria:

* All sites participating in Get With the Guidelines Heart Failure.

Exclusion Criteria:

* Sites in Get With the Guidelines Heart Failure which opt out of participation.

Primary outcomes:
measure: Improvement in the overall opportunity-based composite of measures eligible for intervention (absolute score difference compared to the control arm) based on the existing Get With the Guidelines Heart Failure Achievement Measures and Quality Measures.
timeFrame: 1 year
Secondary outcomes:
measure: Improvement in Defect Free (all or none) score based on the combined Get With the Guidelines Heart Failure Achievement and Quality Measures
timeFrame: 1 year
measure: Improvement in scores of each individual Get With the Guidelines Heart Failure Achievement and Quality Measure
timeFrame: 1 year
measure: Improvement in length of stay and in-patient mortality.
timeFrame: 1 year
Other outcomes:
Locations:
city: Durham
country: United States
facility: Duke Clinical Research Institute
state: North Carolina
Study officials:
affiliation: Duke Clinical Research Institute
name: Eric D Peterson, MD, MPH
role: PRINCIPAL_INVESTIGATOR
References:
citation: DeVore AD, Cox M, Heidenreich PA, Fonarow GC, Yancy CW, Eapen ZJ, Peterson ED, Hernandez AF. Cluster-Randomized Trial of Personalized Site Performance Feedback in Get With The Guidelines-Heart Failure. Circ Cardiovasc Qual Outcomes. 2015 Jul;8(4):421-7. doi: 10.1161/CIRCOUTCOMES.114.001333. Epub 2015 Jul 14.
Clinical trial NCT00704964: Impact of Patient Support by the Medical Staff on Adherence to Therapy With PegIntron Plus Rebetol (Study P04413)
Official title: Impact of Patient Support From Medical Staff on the Adherence to Therapy With PegIntron Plus Rebetol
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hepatitis C
Chronic Hepatitis C
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
First posted: 2008-06-25
Enrollment: 746
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Participants with chronic hepatitis C treated in 44 non-university centers in Germany.

Brief summary: The objective of this study is to assess the impact of participant care and support on treatment adherence. PegIntron pen and Rebetol will be administered to participants with Hepatitis C Virus (HCV) in accordance with approved labeling. Sites will be categorized as providing high vs low level of participant management based on information about the level of participant support and management captured on the site questionnaire. Data on each participant will be collected by a physician on an electronic participant case report form (CRF) and by the participant via a questionnaire. Treatment completion rates will be analyzed based on the high vs low level of participant management.

The hypothesis is that Physicians investing more time and effort into participant management achieve higher treatment completion rates among their hepatitis C patients than physicians offering less participant management measures.


Eligibility criteria: Inclusion Criteria:

* Participants with chronic hepatitis C.

Those participating in patient assistance programs during therapy for hepatitis C.

Exclusion Criteria:

* Participants who have previously been treatment for hepatitis C (non-naïve)

Other exclusion criteria as described in local Summary of Product Characteristics (SPC).

Primary outcomes:
measure: Number of Participants With Biometrical Adherence to Therapy
timeFrame: Up to 48 weeks for Hepatitis C Virus (HCV) genotype 1 or 4 participants and up to 24 weeks for HCV genotype 2 or 3
measure: Number of Participants With Adherence to Therapy According to Physician Approximation
timeFrame: Up to 48 weeks for HCV genotype 1 or 4 participants and up to 24 weeks for HCV genotype 2 or 3
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02792764: Post-Marketing Study to Assess Complication Rates of Oncology Patients With Ports and Peripheral IVs
Official title: A Prospective, Multi-centered Study to Assess the Complication Rates of Oncology Patients Accessed With Peripheral Intravenous Lines Versus Implantable Ports for Chemotherapy Administration
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: PORTs/Peripheral IVs Complication Rates
Keywords: port
peripheral intravenous lines
oncology
Lead sponsor: C. R. Bard
Sponsor class: INDUSTRY
First posted: 2016-06-08
Enrollment: 300
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All subjects who are currently undergoing or has had infusional cancer therapy (solid tumor or hematologic) through a Bard PORT with a distally-valved catheter/open-ended catheter or infusion through a Peripheral IV

Brief summary: This study is to collect current information on complications rates of subjects undergoing chemotherapy administration through Ports and peripheral IVs.


Eligibility criteria: Inclusion Criteria:

* Male or female, age ≥ 21 years
* Subject is currently undergoing or has had infusional cancer therapy (solid tumor or hematologic) through a Bard PORT with a distally-valved catheter/open-ended catheter or infusion through a PIV
* Subject had a chemotherapy regimen consisting of a vesicant and/or irritant
* Subject has signed an Informed Consent Form (ICF) or has had an ICF signed by the subject's legally authorized representative

Exclusion Criteria:

* Subject has/had an implanted non Bard PORT

Primary outcomes:
measure: The rate of adverse events in subjects undergoing chemotherapy administration through PORTs and PIVs.
timeFrame: Through end of chemotherapy, up to 3 years
Secondary outcomes:
measure: The average number of accesses during course of treatment (i.e. - chemotherapy administration, CTs, blood draws, TPN, etc.)
timeFrame: Through end of chemotherapy, up to 3 years
measure: The rate of Vascular Access Device conversion from Peripheral IV to PORT
timeFrame: Through end of chemotherapy, up to 3 years
measure: The average time of vascular access device conversion from Peripheral IV to PORT
timeFrame: Through end of chemotherapy, up to 3 years
Other outcomes:
Locations:
city: Quincy
country: United States
facility: Quincy Medical Group
state: Illinois
city: Shreveport
country: United States
facility: Willis Knighton Cancer Center
state: Louisiana
Study officials:
References:
Clinical trial NCT01808664: Promoting Patient-Centered Counseling to Reduce Inappropriate Diagnostic Tests
Official title: Promoting Patient-Centered Counseling to Reduce Inappropriate Diagnostic Tests: Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Unnecessary Procedures
Low Back Pain
Osteoporosis
Headache
Magnetic Resonance Imaging
Primary Care
Lead sponsor: University of California, Davis
Sponsor class: OTHER
First posted: 2013-03-11
Enrollment: 61
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: In this study, the investigators will develop and evaluate a novel intervention using standardized patients (SPs) -- or actors playing the roles of patients -- to enhance physicians' patient-centered counseling skills regarding two frequently overused, potentially inappropriate services in primary care: magnetic resonance imaging (MRI) for acute low back pain and bone densitometry in women at low-risk for osteoporosis. The investigators will further evaluate whether intervention effects on physician patient-centeredness generalize to counseling regarding other costly, unnecessary diagnostic tests.


Eligibility criteria: Inclusion Criteria:

* Resident physician in family medicine or internal medicine who deliver primary care at one of two hospital-based primary care clinics at the University of California, Davis Medical Center Sacramento

Exclusion Criteria:

* Anticipated graduation in less than one year from enrollment.

Primary outcomes:
measure: Number of inappropriate diagnostic tests ordered
timeFrame: 9 months
Secondary outcomes:
measure: Use of patient-centered counseling techniques
timeFrame: 9 months
measure: Actual diagnostic test ordering among real patients
timeFrame: 9 months post-intervention
Other outcomes:
measure: Standardized Patient Satisfaction
timeFrame: 9 months
Locations:
Study officials:
affiliation: University of California, Davis
name: Joshua J Fenton, MD, MPH
role: PRINCIPAL_INVESTIGATOR
References:
citation: May L, Franks P, Jerant A, Fenton J. Watchful Waiting Strategy May Reduce Low-Value Diagnostic Testing. J Am Board Fam Med. 2016 Nov 12;29(6):710-717. doi: 10.3122/jabfm.2016.06.160056.
citation: Fenton JJ, Kravitz RL, Jerant A, Paterniti DA, Bang H, Williams D, Epstein RM, Franks P. Promoting Patient-Centered Counseling to Reduce Use of Low-Value Diagnostic Tests: A Randomized Clinical Trial. JAMA Intern Med. 2016 Feb;176(2):191-7. doi: 10.1001/jamainternmed.2015.6840.
Clinical trial NCT01141764: Cerebral Metabolic Changes Associated With Thalamic Stimulation
Official title: Cerebral Metabolic Changes Associated With Thalamic Stimulation
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Epilepsy
Keywords: pediatrics
Epilepsy
Deep Brain Stimulation
Positron Emission Tomography
Lead sponsor: The Hospital for Sick Children
Sponsor class: OTHER
Collaborators: name: University Health Network, Toronto
First posted: 2010-06-10
Enrollment: 4
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this research study is to evaluate the brain circuits function and circuits involved in the mechanism of thalamic DBS in patients with medically refractory epilepsy.

Detailed description: Deep brain stimulation (DBS) of the anterior nucleus of the thalamus in patients with medically refractory epilepsy has been shown to be efficacious. Studies have estimated a 46-76% reduction in seizures relative to the baseline. However, the exact anatomic circuitry involved in the mechanism of DBS in epilepsy remains unknown. Positron emission tomography (PET) studies can provide clues to the metabolic activity associated with DBS activation. In our study, patients will be scanned with their DBS electrodes turned "on" and "off". PET data captured during these two distinct states may show characteristic differences in cerebral glucose metabolism and modulatory effects of surrounding cerebral structures, thus providing clues to how DBS works to prevent seizures.

Eligibility criteria: Inclusion Criteria:

* 18-85 years old
* currently have DBS implanted for medically refractory epilepsy
* Women of childbearing age will be required to use established contraceptive methods while enrolled in the study.

Exclusion Criteria:

Patients who:

* are \< 18 years of age or \> 85 years of age
* are medically unstable
* are women who are potentially pregnant, pregnant or nursing
* have had PET imaging within 1 year.

Primary outcomes:
measure: Areas of the brain with low activity
timeFrame: within 30 days of enrollment in the study
Secondary outcomes:
measure: Brain Abnormalities
timeFrame: within 30 days of enrollment in the study
measure: Ability to learn and understand
timeFrame: within 30 days of enrollment in the study
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: The Hospital for Sick Children
state: Ontario
city: Toronto
country: Canada
facility: Toronto Western Hospital
state: Ontario
Study officials:
affiliation: The Hospital for Sick Children, Toronto Canada
name: Elysa Widjaja, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02969564: 18F-NaF-PET/MR vs 99mTc-MDP-SPECT/CT to Detect Bone Metastases in Prostate Cancer Patients.
Official title: 18F-NaF-PET/MR vs 99mTc-MDP-SPECT/CT to Detect Bone Metastases in Prostate Cancer Patients.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Bone Metastases
Prostate Cancer
Keywords: prostate cancer
bone metastases
PET/MRI
Lead sponsor: University Hospital, Geneva
Sponsor class: OTHER
Collaborators: name: University Hospital, Geneva
First posted: 2016-11-21
Enrollment: 12
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Oligo- metastatic patient with prostate cancer and bone lesions (up to five metastases)

Brief summary: The number of metastases in a patient with primary or recurrent prostate cancer has major prognostic implication.

The purpose is to compare, in a pilot study, the diagnostic performance of 18F-NaF-PET/MR with respect to the results of the scintigraphy 99mTc-MDP-SPECT/CT (routine exam) for determining the presence or absence of bone lesions in prostate cancer patient, with up to five metastases (oligo-bone metastatic) based on scintigraphy 99mTc-MDP-SPECT/CT. The gold standard will be a combination of clinical follow-up, additional imaging and biopsy, as indicated by the multidisciplinary discussion at the tumor board. The findings from whole-body 99mTc-MDP-SPECT/CT, 18F-NaF-PET/MR, and the combination of the 2 modalities will be categorized by 2 teams of 2 readers as benign or probably benign, equivocal, or malignant or probably malignant and compared with the results of follow-up for JAFROC and ROC analysis.


Eligibility criteria: Inclusion Criteria:

* Oligo- metastatic patient with prostate cancer and bone lesions (up to five metastases) based on scintigraphy and whole-body SPECT/CT (staging or recurrence).
* Patient must be able to provide informed consent.
* Patient is ≥ 18 years old

Exclusion Criteria:

* Patient with another active malignancy.
* Patient is \< 18 years old
* Patients with contraindications of MRI procedure (metal implants, cardiac pacemakers, old type of prosthesis)
* Patients with severe renal impairment (MDRD \< 30)

Primary outcomes:
measure: Compare the diagnostic performance of 18F-NaF-PET/MR scanning to that of whole body 99mTc-MDP-SPECT/CT for detecting cancer that has spread to the bone (bone metastasis)
timeFrame: through study completion, an average of 2 years
Secondary outcomes:
measure: To assess differences in sensitivity and specificity in detecting bone metastases between the two imaging modalities.
timeFrame: through study completion, an average of 2 years
measure: To determine the number of equivocal and diagnostic tests resulting from the two imaging modalities.
timeFrame: through study completion, an average of 2 years
Other outcomes:
Locations:
city: Geneva
country: Switzerland
facility: Geneva University Hospital
Study officials:
References:
Clinical trial NCT06228664: Bowen Therapy and Foam Rolling in Patients With Text Neck Syndrome
Official title: Comparison of Bowen Therapy and Foam Rolling in Text Neck Syndrome Among Students
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Neck Pain
Keywords: text neck syndrome
neck pain
bowen therapy
foam rolling
Lead sponsor: Riphah International University
Sponsor class: OTHER
First posted: 2024-01-29
Enrollment: 28
Sex: ALL
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aims to compare the effects of both the therapies on postural changes, pain, decreased ROM, and functional disability among students suffering from Text Neck Syndrome.


Eligibility criteria: Inclusion Criteria:

* neck-head trauma
* history of surgical intervention in the neck area
* neurological deficit
* severe neck pain which required medical treatment
* cervical disc disease with radiculopathy
* inflammatory or malignant type of pain
* systematic disease
* scoliosis
* kyphosis.

Exclusion Criteria:

* neck-head trauma
* history of surgical intervention in the neck area
* neurological deficit
* severe neck pain which required medical treatment
* cervical disc disease with radiculopathy
* inflammatory or malignant type of pain
* systematic disease
* scoliosis
* kyphosis.

Primary outcomes:
measure: Neck Disability Index
timeFrame: 6 week
measure: NPRS
timeFrame: 6 week
Secondary outcomes:
Other outcomes:
Locations:
city: Peshawar
country: Pakistan
facility: CECOS university of IT and emerging sciences
state: KPK
Study officials:
affiliation: Riphah International University
name: Asmar Fatima, MS OMPT
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00632164: Sympathetic and Parasympathetic Responses to Specific Chiropractic Adjustments
Official title: Sympathetic and Parasympathetic Responses to Specific Chiropractic Adjustments of Subluxation of the Cervical and Thoracic Spine
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Autonomic Nervous System
Lead sponsor: Sherman College of Straight Chiropractic
Sponsor class: OTHER
First posted: 2008-03-10
Enrollment: 40
Sex: ALL
Minimum age (years): 25
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Random ages 25-55 asymptomatic

Brief summary: A study to determine if a chiropractic adjustment in the cervical spine will effect the parasympathetics and a chiropractic adjustment in the thoracic spine will effect the sympathetics.


Eligibility criteria: Inclusion Criteria:

* age 25-55, asymptomatic

Exclusion Criteria:

* HBP, heart condition

Primary outcomes:
measure: Blood Pressure, Pulse Rate, Heart Rate Variability
Secondary outcomes:
Other outcomes:
Locations:
city: Spartanburg
country: United States
facility: Sherman College
state: South Carolina
Study officials:
affiliation: Sherman College
name: Arlene R Welch, BS, DC
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03860064: Aneuploidy Rates of in Vitro Matured Oocytes
Official title: Aneuploidy Rates of in Vitro Matured Oocytes
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Aneuploidy
Lead sponsor: IVI Barcelona
Sponsor class: OTHER
First posted: 2019-03-01
Enrollment: 60
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Mature ooocytes from the same donors, will be used as control group.

Brief summary: In general, nearly 85% of retrieved oocytes are mature and reproductively useful after the retrieval, whereas the remaining percentage are still at metaphase I or germinal vesicle stage (MI: 4% and GV: 11 %, respectively).

The objective of our study is to assess if immature oocytes co-cultured with autologous cumulus cells is a safer strategy than just leaving the oocytes in standard culture.

Detailed description: Under controlled ovarian stimulation, patients with normal functional ovarian reserves produce a good number of oocytes at retrieval. However, in addition to quantity, oocyte maturity is an important variable for the success of reproductive technologies. In general, nearly 85% of retrieved oocytes are mature and reproductively useful, whereas the remaining percentage are still at metaphase I or germinal vesicle stage (MI: 4% and GV: 11 %, respectively). Due to the limited expectations held for in vitro maturation in said stimulated cycles, the rescue of immature oocytes is not widely used in current clinical practice and these oocytes are usually discarded due to the possibility of abnormal embryonic development or an increased rate of abortion.

The objective of our study is to assess if immature oocytes co-cultured with autologous cumulus cells is a safer strategy than just leaving the oocytes in standard culture.

Eligibility criteria: Inclusion Criteria:

* 18-35-year-old women
* BMI: \>18 and \< 30 kg/m2
* Normal female karyotype
* Normal uterus and ovaries at transvaginal ultrasound

Exclusion Criteria:

* \> 35 years
* PCO syndrome carriers
* Null follicle aspiration
* History of chemotherapy or radiotherapy

Primary outcomes:
measure: Aneuploidy rate
timeFrame: The moment that the PB is extruded (between 1 hour and 50 hours after the denudation)
Secondary outcomes:
Other outcomes:
Locations:
city: Barcelona
country: Spain
facility: Ivi Barcelona
Study officials:
References: